First, for some patients, clinical features such as prostate-specific antigen level, and prostate-specific antigen density could not be included in the prediction model, but they are commonly used by clinicians to assess the aggressiveness of PCa [49, 50]. The gene discussed is KLK3; the disease is posterior cortical atrophy.